Skip to main content

Advertisement

SpringerLink
Log in

In response to: The validity of 18F-GE180 as a TSPO imaging agent

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Zanotti-Fregonara P, Veronese M, Pascual B, Rostomily RC, Turkheimer F, Masdeu JC. The validity of 18F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-4268-4.

    Article  PubMed  Google Scholar 

  2. Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45(8):1423–31.

    Article  PubMed  Google Scholar 

  3. Vomacka L, Albert NL, Lindner S, Unterrainer M, Mahler C, Brendel M, et al. TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7(1):89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Albert NL, Unterrainer M, Fleischmann D, Lindner S, Vettermann F, Brunegraf A, et al. TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44(13):2230–8.

    Article  CAS  PubMed  Google Scholar 

  5. Unterrainer M, Fleischmann D, Diekmann C, Vomacka L, Lindner S, Vettermann F, et al. Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study. Eur J Nucl Med Mol Imaging. 2019;46(3):580–90.

    Article  PubMed  Google Scholar 

  6. Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R, Tonn JC, et al. Detection of cerebrospinal fluid dissemination of recurrent glioblastoma using TSPO-PET with 18F-GE-180. Clin Nucl Med. 2018;43(7):518–9.

    Article  PubMed  Google Scholar 

  7. Beyer L, Brendel M, Rohrer G, Sonnenfeld S, Nübling G, Lindner S, et al. Translocator protein 18kDa (TSPO) expression in patients with clinically diagnosed progressive Supranuclear palsy. J Nucl Med. 2018;59(Suppl 1):1700.

    Google Scholar 

  8. Schöberl F, Levin J, Remi J, Goldschagg N, Eren O, Okamura N, et al. IgLON5: a case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology. 2018;91(4):180–2.

    Article  PubMed  Google Scholar 

  9. Mahler C, Unterrainer M, Muth C, Egensperger R, Vomacka L, Lindner S, et al. Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET. Neurology. 2018;91(20):936–7.

    Article  PubMed  Google Scholar 

  10. Mahler C, Schumacher M, Unterrainer M, Vomacka L, Lindner S, Rupprecht R, et al. Monitoring CNS inflammatory activity in natalizumab related PML with TSPO-PET. Mult Scler J. 2018;24:37–8.

    Google Scholar 

  11. Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, et al. Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple-tracer PET study. J Nucl Med. 2016;57(6):954–60.

    Article  CAS  PubMed  Google Scholar 

  12. Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, et al. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification. Neuroimage. 2018;165:83–91.

    Article  PubMed  Google Scholar 

  13. Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22(2):191–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sridharan S, Lepelletier F-X, Trigg W, Banister S, Reekie T, Kassiou M, et al. Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. Mol Imaging Biol. 2017;19(1):77–89.

    Article  CAS  PubMed  Google Scholar 

  15. Cumming P, Burgher B, Patkar O, Breakspear M, Vasdev N, Thomas P, et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab. 2018;38(2):204–24.

    Article  PubMed  Google Scholar 

  16. Sridharan S, Raffel J, Nandoskar A, Record C, Brooks D, Owen D, et al. Confirmation of specific binding of the 18 kDa translocator protein (TSPO) radioligand [F-18] GE-180: a blocking study using XDB173 in multiple sclerosis normal appearing white and grey matter.  Mol Imaging Biol. 2019;24:421–2. https://doi.org/10.1007/s11307-019-01323-8

  17. Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, et al. Kinetic analysis of the translocator protein positron emission tomography ligand [18F] GE-180 in the human brain. Eur J Nucl Med Mol Imaging. 2016;43(12):2201–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein. J Nucl Med. 2016;57(11):1753–9.

    Article  CAS  PubMed  Google Scholar 

  19. Jaremko Ł, Jaremko M, Giller K, Becker S, Zweckstetter M. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science. 2014;343(6177):1363–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jaremko M, Jaremko Ł, Giller K, Becker S, Zweckstetter M. Structural integrity of the A147T polymorph of mammalian TSPO. Chembiochem. 2015;16(10):1483–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

    Nathalie L. Albert, Marcus Unterrainer, Matthias Brendel, Lena Kaiser & Peter Bartenstein

  2. Department for NMR-Based Structural Biology, Max Planck Institute for Biophysical Chemistry, Goettingen, Germany

    Markus Zweckstetter

  3. German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany

    Markus Zweckstetter

  4. Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland

    Paul Cumming

  5. School of Psychology and Counselling and IHBI, Queensland University of Technology, Brisbane, Australia

    Paul Cumming

Authors
  1. Nathalie L. Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Unterrainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Brendel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lena Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Zweckstetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul Cumming
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie L. Albert.

Ethics declarations

Conflicts of interest

N.L.A. is a member of the Neuroimaging Committee of the EANM. P.B. has received a speaker honorarium from GE Healthcare. All other authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albert, N.L., Unterrainer, M., Brendel, M. et al. In response to: The validity of 18F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging 46, 1208–1211 (2019). https://doi.org/10.1007/s00259-019-04294-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04294-8

Search

Navigation